A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 Planned number of patients changed from 24 to 35.
- 26 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.